243 related articles for article (PubMed ID: 35303922)
1. Variability of α/β ratios for prostate cancer with the fractionation schedule: caution against using the linear-quadratic model for hypofractionated radiotherapy.
Cui M; Gao XS; Li X; Ma M; Qi X; Shibamoto Y
Radiat Oncol; 2022 Mar; 17(1):54. PubMed ID: 35303922
[TBL] [Abstract][Full Text] [Related]
2. The minimal FLASH sparing effect needed to compensate the increase of radiobiological damage due to hypofractionation for late-reacting tissues.
Böhlen TT; Germond JF; Bourhis J; Bailat C; Bochud F; Moeckli R
Med Phys; 2022 Dec; 49(12):7672-7682. PubMed ID: 35933554
[TBL] [Abstract][Full Text] [Related]
3. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.
Brand DH; Tree AC; Ostler P; van der Voet H; Loblaw A; Chu W; Ford D; Tolan S; Jain S; Martin A; Staffurth J; Camilleri P; Kancherla K; Frew J; Chan A; Dayes IS; Henderson D; Brown S; Cruickshank C; Burnett S; Duffton A; Griffin C; Hinder V; Morrison K; Naismith O; Hall E; van As N;
Lancet Oncol; 2019 Nov; 20(11):1531-1543. PubMed ID: 31540791
[TBL] [Abstract][Full Text] [Related]
4. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.
Widmark A; Gunnlaugsson A; Beckman L; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Fransson P; Tavelin B; Norman D; Zackrisson B; Anderson H; Kjellén E; Franzén L; Nilsson P
Lancet; 2019 Aug; 394(10196):385-395. PubMed ID: 31227373
[TBL] [Abstract][Full Text] [Related]
5. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial.
Incrocci L; Wortel RC; Alemayehu WG; Aluwini S; Schimmel E; Krol S; van der Toorn PP; Jager H; Heemsbergen W; Heijmen B; Pos F
Lancet Oncol; 2016 Aug; 17(8):1061-1069. PubMed ID: 27339116
[TBL] [Abstract][Full Text] [Related]
6. Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 1.4 (0.9-2.2) Gy.
Miralbell R; Roberts SA; Zubizarreta E; Hendry JH
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):e17-24. PubMed ID: 21324610
[TBL] [Abstract][Full Text] [Related]
7. Technical Note: Break-even dose level for hypofractionated treatment schedules.
Böhlen TT; Germond JF; Bourhis J; Vozenin MC; Bailat C; Bochud F; Moeckli R
Med Phys; 2021 Nov; 48(11):7534-7540. PubMed ID: 34609744
[TBL] [Abstract][Full Text] [Related]
8. What hypofractionated protocols should be tested for prostate cancer?
Fowler JF; Ritter MA; Chappell RJ; Brenner DJ
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):1093-104. PubMed ID: 12829147
[TBL] [Abstract][Full Text] [Related]
9. Conversion and validation of rectal constraints for prostate carcinoma receiving hypofractionated carbon-ion radiotherapy with a local effect model.
Wang W; Li P; Sheng Y; Huang Z; Zhao J; Hong Z; Shahnazi K; Jiang GL; Zhang Q
Radiat Oncol; 2021 Apr; 16(1):72. PubMed ID: 33849589
[TBL] [Abstract][Full Text] [Related]
10. Radiation pneumonitis after hypofractionated radiotherapy: evaluation of the LQ(L) model and different dose parameters.
Borst GR; Ishikawa M; Nijkamp J; Hauptmann M; Shirato H; Bengua G; Onimaru R; de Josien Bois A; Lebesque JV; Sonke JJ
Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1596-603. PubMed ID: 20231066
[TBL] [Abstract][Full Text] [Related]
11. Compatibility of the linear-quadratic formalism and biologically effective dose concept to high-dose-per-fraction irradiation in a murine tumor.
Otsuka S; Shibamoto Y; Iwata H; Murata R; Sugie C; Ito M; Ogino H
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1538-43. PubMed ID: 22115556
[TBL] [Abstract][Full Text] [Related]
12. Hypofractionation for clinically localized prostate cancer.
Hickey BE; James ML; Daly T; Soh FY; Jeffery M
Cochrane Database Syst Rev; 2019 Sep; 9(9):CD011462. PubMed ID: 31476800
[TBL] [Abstract][Full Text] [Related]
13. Clinical estimation of α/β values for prostate cancer from isoeffective phase III randomized trials with moderately hypofractionated radiotherapy.
Datta NR; Stutz E; Rogers S; Bodis S
Acta Oncol; 2018 Jul; 57(7):883-894. PubMed ID: 29405785
[TBL] [Abstract][Full Text] [Related]
14. Compatibility of the repairable-conditionally repairable, multi-target and linear-quadratic models in converting hypofractionated radiation doses to single doses.
Iwata H; Matsufuji N; Toshito T; Akagi T; Otsuka S; Shibamoto Y
J Radiat Res; 2013 Mar; 54(2):367-73. PubMed ID: 23077237
[TBL] [Abstract][Full Text] [Related]
15. Effect of patient variation on standard- and hypo-fractionated radiotherapy of prostate cancer.
Xiong W; Li J; Ma CM
Phys Med Biol; 2005 Apr; 50(7):1483-92. PubMed ID: 15798338
[TBL] [Abstract][Full Text] [Related]
16. Effect of reoxygenation on hypofractionated radiotherapy of prostate cancer.
Kuperman VY; Lubich LM
Med Phys; 2020 Oct; 47(10):5383-5391. PubMed ID: 32583529
[TBL] [Abstract][Full Text] [Related]
17. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.
Aluwini S; Pos F; Schimmel E; van Lin E; Krol S; van der Toorn PP; de Jager H; Dirkx M; Alemayehu WG; Heijmen B; Incrocci L
Lancet Oncol; 2015 Mar; 16(3):274-83. PubMed ID: 25656287
[TBL] [Abstract][Full Text] [Related]
18. Tumor Control Probability Modeling and Systematic Review of the Literature of Stereotactic Body Radiation Therapy for Prostate Cancer.
Royce TJ; Mavroidis P; Wang K; Falchook AD; Sheets NC; Fuller DB; Collins SP; El Naqa I; Song DY; Ding GX; Nahum AE; Jackson A; Grimm J; Yorke E; Chen RC
Int J Radiat Oncol Biol Phys; 2021 May; 110(1):227-236. PubMed ID: 32900561
[TBL] [Abstract][Full Text] [Related]
19. Hypofractionation: what does it mean for prostate cancer treatment?
Liao Y; Joiner M; Huang Y; Burmeister J
Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):260-8. PubMed ID: 19879698
[TBL] [Abstract][Full Text] [Related]
20. Higher-than-expected severe (Grade 3-4) late urinary toxicity after postprostatectomy hypofractionated radiotherapy: a single-institution analysis of 1176 patients.
Cozzarini C; Fiorino C; Deantoni C; Briganti A; Fodor A; La Macchia M; Noris Chiorda B; Rancoita PM; Suardi N; Zerbetto F; Calandrino R; Montorsi F; Di Muzio N
Eur Urol; 2014 Dec; 66(6):1024-30. PubMed ID: 24985964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]